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Epidemic meningitis has posed a recurrent threat for more 
than a century for the approximately 430 million people living 
in the 26 countries in the sub-Saharan region of Africa known 
as the “meningitis belt.” This population experiences high rates 
of endemic meningitis, annual seasonal outbreaks, and explo-
sive epidemics occurring every 5–12 years. Hope to eliminate 
this devastating public health threat came in the form of a 
novel meningococcal serogroup A  conjugate vaccine (MACV 
[MenAfriVac]) developed by the Meningitis Vaccine Project 
(MVP; available at: http://www.meningvax.org) specifically for 
use in the meningitis belt and priced at less than $1.00 per dose 
[1]. Licensed in 2009, MACV was subsequently prequalified by 
the World Health Organization (WHO) on the basis of its safety 
and immunogenicity data but without phase 3 efficacy studies. 
Starting in 2010, MACV was rolled out across the meningitis 
belt via mass campaigns to vaccinate all persons 1–29 years of 
age. By the end of 2018, >300 million people in 22 African coun-
tries had been immunized with MACV [2]. The vaccine has 
been a remarkable public health success, effectively eliminating 
serogroup A meningitis epidemics in sub-Saharan Africa [3].
Recognizing the need for rigorous postrollout surveillance 
and research to demonstrate the direct and indirect effectiveness 
of MACV beyond the conclusion of the MVP [4–6], the Bill and 
Melinda Gates Foundation awarded a grant in October 2013 to 
establish the MenAfriNet Consortium (available at: http://www.
menafrinet.org). MenAfriNet is an international consortium 
led and implemented by the African Ministries of Health, the 
Agence de Médecine Préventive, the Centers for Disease Control 
and Prevention (CDC), and the WHO, with support and collab-
oration from other international and nongovernmental organi-
zations. By implementing a surveillance and research platform 
in 5 African meningitis belt countries (Burkina Faso, Chad, 
Mali, Niger, and Togo), MenAfriNet aimed to strengthen case-
based meningitis surveillance, assess changes in meningitis ep-
idemiology and MACV impact, and inform vaccine policy and 
development. This supplement aims to summarize the work 
conducted in the first 5 years of MenAfriNet, including regional 
and country perspectives on the MenAfriNet strategy of reinfor-
cing case-based surveillance, updates on bacterial meningitis 
epidemiology and MACV impact, examples of research that lev-
eraged the MenAfriNet platform, and future directions toward 
defeating epidemic meningitis in the African meningitis belt.
MenAfriNet took an innovative approach to vaccine evalu-
ation by strengthening existing country-level meningitis sur-
veillance systems and laboratory capacity to gather high quality 
case-level data and leveraged this surveillance platform to an-
swer critical research questions about vaccine effectiveness 
[7–10]. The MenAfriNet approach has focused on country 
ownership of activities, planning, and budgeting and has made 
significant progress toward stronger, sustainable public health 
surveillance systems in Burkina Faso, Chad, Mali, Niger, and 
Togo [7, 11–14]. Secondarily, MenAfriNet has had a positive im-
pact on other countries in the region, including Benin, Ghana, 
Guinea, and Nigeria, through the distribution of MenAfriNet-
developed surveillance and laboratory tools and protocols, as 
well as regional trainings and technical assistance provided by 
consortium members [10].
A number of articles in this supplement present evidence of 
MACV’s substantial and ongoing impact on meningococcal 
serogroup A disease and progress toward elimination of sero-
group A  epidemics in the meningitis belt [14–16]. To date, 
MenAfriNet data have directly informed numerous public 
health actions, including policies for the use of MACV to pro-
tect new birth cohorts through introduction into routine im-
munization programs and catch-up campaigns, the detection 
and response to epidemics due to new emerging strains of 
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non-A meningococcal serogroups, and the development and 
use of new vaccines [17–22].
Now at the conclusion of 5  years of experience with the 
MenAfriNet platform, this supplement was organized as a forum 
to share the achievements and lessons learned implementing the 
MenAfriNet strategy to strengthen national systems of surveil-
lance in Africa. Contents include an overview of project imple-
mentation and impact in the 5 MenAfriNet countries, reports 
on epidemiologic issues from each of the project countries, spe-
cific research projects that provide insights into the evolving ep-
idemiology of non-A serogroup meningitis and pneumococcal 
disease in these countries, and a look toward the future goal of 
eliminating meningitis in the region. These achievements and 
lessons, combined with a current examination of regional men-
ingitis epidemiology and ongoing monitoring of the impact of 
existing vaccine programs, will inform the development of new 
vaccines and strategies to help realize the dream of an Africa 
free of epidemic meningitis [18, 23].
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